Chimeric Antigen Receptor T-Cell Therapy–Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma
Sarju Ganatra, Robert Redd, Salim S. Hayek, Rohan Parikh, Tariq U. Azam, Gregory A. Yanik, Lauren Spendley, Sarah Nikiforow, Caron A. Jacobson, Anju Nohria
Abstract
cardiotoxicity cytokine release syndrome heart failure lymphoma, non-Hodgkin receptors, chimeric antigen tisagenlecleucel A doptive cell therapy using chimeric antigen receptor (CAR) T cells augments the ability of the patient's immune system to recognize and destroy cancer cells. Genetically modified autologous T-cell agents that target CD-19, tisagenlecleucel and axicabtagene ciloleucel, are currently approved for the treatment of children with B-cell acute lymphocytic leukemia and adults with aggressive B-cell lymphoma. Cytokine release syndrome (CRS) is a frequent adverse effect of CAR T-cell therapy and has been associated with cardiotoxicity. In this study, we examined the incidence and impact of CAR T-cell therapy-associated cardiomyopathy.